Formulation and evaluation of the vascular endothelial growth factor loaded polycaprolactone nanoparticles

Abstract In an attempt to increase molecular stability and provide controlled release, vascular endothelial growth factor (VEGF) was encapsulated into polycaprolactone (PCL) nanoparticles. Both VEGF-free and VEGF-loaded PCL nanoparticles were formulated by w/o/w double emulsion of the dichloromethan...

Full description

Saved in:
Bibliographic Details
Main Authors: Oya Kerimoğlu (Author), Setenay Özer-Önder (Author), Emine Alarçin (Author), Seher Karsli (Author)
Format: Book
Published: Universidade de São Paulo, 2022-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d3cb1c0d34ba4cda8b5e6f92fc8972b7
042 |a dc 
100 1 0 |a Oya Kerimoğlu  |e author 
700 1 0 |a Setenay Özer-Önder  |e author 
700 1 0 |a Emine Alarçin  |e author 
700 1 0 |a Seher Karsli  |e author 
245 0 0 |a Formulation and evaluation of the vascular endothelial growth factor loaded polycaprolactone nanoparticles 
260 |b Universidade de São Paulo,   |c 2022-08-01T00:00:00Z. 
500 |a 2175-9790 
500 |a 10.1590/s2175-97902022e19660 
520 |a Abstract In an attempt to increase molecular stability and provide controlled release, vascular endothelial growth factor (VEGF) was encapsulated into polycaprolactone (PCL) nanoparticles. Both VEGF-free and VEGF-loaded PCL nanoparticles were formulated by w/o/w double emulsion of the dichloromethane-water system in the presence of polyvinyl alcohol (PVA) and rat serum albumin. To achieve the optimal formulation concerning particle size and monodispersity, studies were carried out with different formulation parameters, including PVA concentration, homogenization time and rate. Scanning electron microscopy and dynamic light scattering analysis showed respectively that particles had a spherical shape with a smooth surface and particle size varying between 58.68-751.9 nm. All of the formulations were negatively charged according to zeta potential analysis. In vitro release study was performed in pH 7.4 phosphate-buffered saline at 37°C and released VEGF amount was measured by enzyme-linked immunosorbent assay (ELISA) method. At the end of the 35th day, 10% of total encapsulated VEGF was released with a sustained-release profile, which fitted the Korsmeyer-Peppas kinetic model. The bioactivation of the nanoparticles was evaluated using XTT and ELISA methods. As a result, the released VEGF was biologically active and also VEGF loaded PCL nanoparticles enhanced proliferation of the human umbilical vein endothelial cells in cell culture. 
546 |a EN 
690 |a Nanoparticles 
690 |a Polycaprolactone 
690 |a VEGF 
690 |a Double emulsion method 
690 |a Bioactivity 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Brazilian Journal of Pharmaceutical Sciences, Vol 58 (2022) 
787 0 |n http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100661&tlng=en 
787 0 |n https://doaj.org/toc/2175-9790 
856 4 1 |u https://doaj.org/article/d3cb1c0d34ba4cda8b5e6f92fc8972b7  |z Connect to this object online.